Athenex, Inc. Intellectual Property Contracts & Agreements
37 Contracts & Agreements
- License Agreements (37 contracts)
- First Supplemental Agreement to License Agreement by and among Athenex, Inc. and Chongqing Taihao Pharmaceutical Co. Ltd. and Guangzhou Xiangxue Pharmaceutical Co., Ltd., dated... (Filed With SEC on March 16, 2022)
- Third Supplemental Agreement and Amendment to License Agreement by and among Athenex, Inc. and Chongqinq Guangzhou Xiangxue Pharmaceutical Co., Ltd., dated November 8, 2021 (Filed With SEC on March 16, 2022)
- Second Amended and Restated Exclusive License and Option Agreement between Baylor College of Medicine and Kuur Therapeutics Limited, dated October 12, 2021 (Filed With SEC on March 16, 2022)
- Amended and Restated Exclusive License and Option Agreement between Baylor College of Medicine and Kuur Therapeutics Limited, dated February 28, 2020 (Filed With SEC on August 5, 2021)
- Second Amendment to License Agreement dated as of February 15, 2021 by and between Athenex, Inc. and PharmaEssentia Corp (Filed With SEC on May 6, 2021)
- Second Supplemental Agreement to License Agreement dated December 12, 2019 by and among Athenex, Inc. and Chongqing Taihao Pharmaceutical Co. Ltd. and Guangzhou Xiangxue... (Filed With SEC on August 6, 2020)
- Second Amendment to License Agreement by and between Athenex, Inc. and PharmaEssentia Corp., effective as of November 27, 2018 (Filed With SEC on May 7, 2020)
- License Agreement by and between Kinex Pharmaceuticals, Inc. and PharmaEssentia Corp., effective as of December 16, 2013 (Filed With SEC on May 7, 2020)
- License Agreement by and between Kinex Pharmaceuticals, LLC and Guangzhou Xiangxue New Drug Discovery and Development Company Limited, effective as of May 6, 2012 (Filed With SEC on May 7, 2020)
- License Agreement between the Company and Guangzhou Xiangxue Pharmaceutical Co., Ltd. dated December 12, 2019 (Filed With SEC on December 16, 2019)
- Second Amendment to License and Development Agreement by and between Athenex, Inc., Almirall, S.A., and Aqua Pharmaceuticals LLC, dated as of June 18, 2019 (Filed With SEC on August 7, 2019)
- Fifth Amendment to License Agreement by and between Athenex, Inc. and Hanmi Pharmaceutical Co. Ltd., effective as of September 4, 2018 (Filed With SEC on March 11, 2019)
- Second Amendment to License Agreement by and between Athenex, Inc. and PharmaEssentia Corp., effective as of November 27, 2018 (Filed With SEC on March 11, 2019)
- License Agreement, dated as of December 30, 2018 by and between Athenex, Inc. and Chongqing Taihao Pharmaceutical Co. Ltd (Filed With SEC on January 3, 2019)
- First Amendment to License and Development Agreement by and between Athenex, Inc., Almirall, S.A., and Aqua Pharmaceuticals LLC, dated as of September 26, 2018 (Filed With SEC on November 14, 2018)
- License Agreement dated as of June 29, 2018, by and between Xiangxue Life Sciences Ltd. and Axis Therapeutics Limited (Filed With SEC on July 2, 2018)
- License Agreement dated as of June 29, 2018, by and between Athenex Therapeutics Limited and Avalon Polytom (HK) Limited Pegtomarginase (Filed With SEC on July 2, 2018)
- License and Supply Agreement dated as of June 29, 2018, by and between Athenex Therapeutics Limited and Avalon HepaPOC Limited Galactose Meter and Strip (Filed With SEC on July 2, 2018)
- License and Development Agreement by and between Athenex, Inc., Almirall, S.A. and Aqua Pharmaceuticals LLC., dated as of December 11, 2017 (Filed With SEC on March 26, 2018)
- License and Development Agreement, dated as of December 11, 2017, by and between Athenex, Inc., Almirall, S.A. and Aqua Pharmaceuticals LLC (Filed With SEC on December 15, 2017)
- BINDING TERM SHEET FOR LICENSE dated May 5, 2017 by and between ATHENEXPHARMACEUTICAL DIVISION, LLC (Athenex) and GLAND PHARMA LIMITED (Gland) Definitions (Filed With SEC on June 2, 2017)
- LICENSE AGREEMENT by andbetween HANMI PHARMACEUTICAL LTD. and KINEX PHARMACEUTICALS,LLC ORASCOVERY PROGRAM (Filed With SEC on May 12, 2017)
- FIRST AMENDMENT TO LICENSE AGREEMENT (Filed With SEC on May 12, 2017)
- SECOND AMENDMENT TO LICENSE AGREEMENT (Filed With SEC on May 12, 2017)
- THIRD AMENDMENT TO LICENSE AGREEMENT (Filed With SEC on May 12, 2017)
- FOURTH AMENDMENT TO LICENSE AGREEMENT (Filed With SEC on May 12, 2017)
- LICENSE AGREEMENT by andbetween HANMI PHARMACEUTICAL CO., LTD. and KINEX THERAPEUTICS (HK)LIMITED and KINEXPHARMACEUTICALS, INC. (as guarantor) ON ORASCOVERY PROGRAM MAINLAND... (Filed With SEC on May 12, 2017)
- LICENSE AGREEMENT by andbetween KINEX PHARMACEUTICALS, LLC and HANMI PHARMACEUTICAL LTD. (Filed With SEC on May 12, 2017)
- LICENSE AGREEMENT by andbetween KINEX PHARMACEUTICALS, LLC and PHARMAESSENTIA CORP 8 December, 2011 (Filed With SEC on May 12, 2017)
- FIRST AMENDMENT TO LICENSE AGREEMENT (Filed With SEC on May 12, 2017)
- LICENSE AGREEMENT byand between KINEX PHARMACEUTICALS, INC. and PHARMAESSENTIACORP December 16, 2013 (Filed With SEC on May 12, 2017)
- FIRST AMENDMENT TO LICENSE AGREEMENT (Filed With SEC on May 12, 2017)
- LICENSE AGREEMENT by andbetween Kinex Pharmaceuticals, INC. and ZenRx Limited April 25, 2013 (Filed With SEC on May 12, 2017)
- LICENSE AGREEMENT by andbetween KINEX PHARMACEUTICALS, LLC and GUANGZHOU XIANGXUE NEWDRUG DISCOVERY AND DEVELOPMENT COMPANY LIMITED May 6th, 2012 (Filed With SEC on May 12, 2017)
- BINDING TERM SHEET FOR LICENSE dated August 1, 2016 by and between ATHENEXPHARMACEUTICAL DIVISION, LLC (Athenex) and GLAND PHARMA LIMITED (Gland) Definitions (Filed With SEC on May 12, 2017)
- BINDING TERM SHEET FOR LICENSE dated August 26, 2016 by and between ATHENEXPHARMACEUTICAL DIVISION, LLC (Athenex) and GLAND PHARMA LIMITED (Gland) (together, the Parties, and each... (Filed With SEC on May 12, 2017)
- BINDING TERM SHEET FOR LICENSE dated February 22, 2017 by and between ATHENEXPHARMACEUTICAL DIVISION, LLC (Athenex) and GLAND PHARMA LIMITED (Gland) Definitions (Filed With SEC on May 12, 2017)
